{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:44:25Z","timestamp":1782521065541,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T00:00:00Z","timestamp":1268870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s12185-010-0549-1","type":"journal-article","created":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T00:38:00Z","timestamp":1268786280000},"page":"630-635","source":"Crossref","is-referenced-by-count":19,"title":["Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy"],"prefix":"10.1007","volume":"91","author":[{"given":"Kazuko","family":"Kudo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahito","family":"Hama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruriko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Bessho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shosuke","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitoshi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Tawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Tsukimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,18]]},"reference":[{"key":"549_CR1","first-page":"4","volume":"73","author":"L Devlin","year":"2004","unstructured":"Devlin L, Morrison PJ. Accuracy of the clinical diagnosis of Down syndrome. Ulster Med J. 2004;73:4\u201312.","journal-title":"Ulster Med J"},{"key":"549_CR2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/sj.leu.2401754","volume":"14","author":"S Kojima","year":"2000","unstructured":"Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukaemia and myelodysplastic syndrome in children with Down\u2019s syndrome. Leukemia. 2000;14:786\u201391.","journal-title":"Leukemia"},{"key":"549_CR3","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1200\/JCO.2007.12.3687","volume":"25","author":"K Kudo","year":"2007","unstructured":"Kudo K, Kojima S, Tabuchi K, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukaemia: the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2007;25:5442\u20137.","journal-title":"J Clin Oncol"},{"key":"549_CR4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2007.13.2209","volume":"26","author":"MM O\u2019Brien","year":"2008","unstructured":"O\u2019Brien MM, Taub JW, Chang MN, et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children\u2019s Oncology Group Study POG 9421. J Clin Oncol. 2008;26:414\u201320.","journal-title":"J Clin Oncol"},{"key":"549_CR5","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2003.08.060","volume":"21","author":"AS Gamis","year":"2003","unstructured":"Gamis AS, Woods WG, Alonzo TA, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children\u2019s Cancer Group Study 2891. J Clin Oncol. 2003;21:3415\u201322.","journal-title":"J Clin Oncol"},{"issue":"5","key":"549_CR6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00277-005-0045-5","volume":"85","author":"L Abildgaard","year":"2006","unstructured":"Abildgaard L, Ellebaek E, Gustafsson G, et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol. 2006;85(5):275\u201380.","journal-title":"Ann Hematol"},{"key":"549_CR7","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/sj.leu.2403814","volume":"19","author":"U Creutzig","year":"2005","unstructured":"Creutzig U, Reinhardt D, Diekamp S, et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005;19:1355\u201360.","journal-title":"Leukemia."},{"key":"549_CR8","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2141.2005.05906.x","volume":"132","author":"A Rao","year":"2006","unstructured":"Rao A, Hills RK, Stiller C, et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol. 2006;132:576\u201383.","journal-title":"Br J Haematol"},{"key":"549_CR9","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/1097-0142(19871115)60:10<2515::AID-CNCR2820601028>3.0.CO;2-F","volume":"60","author":"JH Simon","year":"1987","unstructured":"Simon JH, Tebbi CK, Freeman AI, et al. Acute megakaryoblastic leukaemia associated with mosaic Down\u2019s syndrome. Cancer. 1987;60:2515\u201320.","journal-title":"Cancer"},{"key":"549_CR10","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2008.18.7948","volume":"27","author":"I Tsukimoto","year":"2009","unstructured":"Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007\u201313.","journal-title":"J Clin Oncol"},{"key":"549_CR11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"549_CR12","first-page":"1598","volume":"92","author":"A Iizuka","year":"1988","unstructured":"Iizuka A, Nagao T. A case of acute megakaryoblastic leukaemia associated with mosaic Down\u2019s syndrome. Jpn J Pediatr Hematol. 1988;92:1598\u2013603.","journal-title":"Jpn J Pediatr Hematol"},{"key":"549_CR13","first-page":"114","volume":"4","author":"M Kurosaki","year":"1990","unstructured":"Kurosaki M, Sugita K, Ohneda S, et al. A case of megakaryoblastic leukaemia after recovering from transient abnormal myelopoiesis with mosaic Down\u2019s syndrome. Jpn J Pediatr Hematol. 1990;4:114\u20139.","journal-title":"Jpn J Pediatr Hematol"},{"key":"549_CR14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/10428199509056843","volume":"17","author":"JJ Doyle","year":"1995","unstructured":"Doyle JJ, Thorner P, Poon A, et al. Transient leukaemia followed by megakaryoblastic leukaemia in a child with mosaic Down syndrome. Leukemia Lymphoma. 1995;17:345\u201350.","journal-title":"Leukemia Lymphoma"},{"key":"549_CR15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ajmg.1320570403","volume":"57","author":"CG Palmer","year":"1995","unstructured":"Palmer CG, Blouin JL, Bull MJ, et al. Cytogenetic and molecular analysis of a ring (21) in a patient with partial trisomy 21 and megakaryocytic leukaemia. Am J Med Genet. 1995;57:527\u201336.","journal-title":"Am J Med Genet"},{"key":"549_CR16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mpo.10102","volume":"41","author":"HH Punnett","year":"2003","unstructured":"Punnett HH, Dampier C. Trisomy 11 limited to trisomy 21 cells in a mosaic Down syndrome child with acute myeloid leukaemia. Med Pediatr Oncol. 2003;41:69\u201370.","journal-title":"Med Pediatr Oncol"},{"key":"549_CR17","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/sj.leu.2405060","volume":"22","author":"H Hasle","year":"2008","unstructured":"Hasle H, Abrahamsson J, Arola M, et al. Myeloid leukemia in children 4\u00a0years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia. 2008;22:1428\u201330.","journal-title":"Leukemia."},{"key":"549_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/pbc.20161","volume":"44","author":"C Sandoval","year":"2005","unstructured":"Sandoval C, Pine SR, Guo Q, et al. Tetrasomy 21 transient leukaemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature. Pediatr Blood Cancer. 2005;44:85\u201391.","journal-title":"Pediatr Blood Cancer"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-010-0549-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0549-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:01:31Z","timestamp":1559451691000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-010-0549-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,18]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1007\/s12185-010-0549-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,18]]}}}